Five consecutive years of double-digit earnings growth

Top-tier performance in 2019, outstanding execution and successful launches from important new therapies position AbbVie for continued growth into 2020.

For a complete look at our 2019 performance, our earnings press release is located here.

Delivering on our commitments

Since 2013, we have consistently demonstrated our ability to deliver on our commitments and 2019 was no exception, as we delivered our fifth consecutive year of double-digit adjusted earnings per share growth.

Our strong financial performance supports our mission to discover and develop a consistent stream of innovative new medicines and drive a remarkable impact for patients.

We are on track for continued growth in 2020 with our adjusted earnings per share outlook that exceeds analyst expectations.

Growth over 2019

Compelling pipeline

AbbVie has a diverse and rich pipeline that ensures we will continue to be able to positively impact the patients we serve and ensure growth over the long term. Over the past 7 years, our pipeline has produced important new therapies that advance treatment options for critical medical conditions.

We continue to invest in transformative science to fuel our pipeline of innovative treatments for patients across several key therapeutic areas.  Learn more about our pipeline here.

The combination of our innovation and commercial execution has resulted in a portfolio of new and differentiated medicines that benefit millions of patients. Revenues from products launched since inception have been steadily increasing each year and in 2019, revenues from those products grew to $9 billion.

Continued dividend growth

A strong and growing dividend is an important hallmark of our investment identity.  In 2019, we increased our quarterly dividend by 10.3 percent. Since 2013, our quarterly dividend has nearly tripled from $0.40 to $1.18 per share.

 

For Investor and Media Use Only—Not For Promotional Use